BOSTON, Oct. 21, 2019 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical
company dedicated to the discovery and development of
groundbreaking therapies to treat cystic fibrosis (CF) and other
diseases caused by dysfunctional protein processing, today
announced that the Company will host a Cystic Fibrosis Summit. The
event, titled "Worlds Apart: Bridging Global Disparity in CF
Treatment," is scheduled for Monday, October
28, 2019 from 8:00 – 10:45 a.m.
ET at Convene at 605 Third Avenue, New York City.
Summit participants scheduled to speak include:
Brad Dell, person with CF
(US)
Damian Downey, M.D., Clinical Senior
Lecturer in Respiratory Medicine, Queen's University Belfast
(UK)
Patrick Flume, M.D., Professor of Medicine and Pediatrics,
Medical University of South Carolina
(US)
Isabelle Jani-Friend, person with CF
(UK)
Juliana Keeping, mother of a person
with CF (US)
Luisa Palazola, person with CF
(US)
A live video webcast of the event will begin at 8:00 a.m. ET and will be available on the
Company's website,
http://ir.proteostasis.com/news-releases/upcoming-events. A replay
of the webcast will be available on the Company's website following
the event.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. For
more information, visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation,
statements regarding the expected presentation at an upcoming
conference. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include,
without limitation, the potential of our proprietary combination
therapies for the treatment of CF, the potential benefit of our
proprietary combination therapies to patients, expected timing of
patient enrollment in, data from, the completion of, our clinical
studies and cohorts for our clinical programs, including our
planned Phase 2 program and initiation of a pivotal study, the
possibility final or future results from our drug candidate trials
(including, without limitation, longer duration studies) do not
achieve positive results or are materially and negatively different
from or not indicative of the preliminary results reported by the
Company (noting that these results are based on a small number of
patients and small data set), uncertainties inherent in the
execution and completion of clinical trials (including, without
limitation, the possibility that FDA or other regulatory agency
comments delay, change or do not permit trial commencement, or
intended label, or the FDA or other regulatory agency requires us
to run cohorts sequentially or conduct additional cohorts or
pre-clinical or clinical studies), in the enrollment of CF patients
in our clinical trials in a competitive clinical environment, in
the timing of availability of trial data, in the results of the
clinical trials, in possible adverse events from our trials, in the
actions of regulatory agencies, in the endorsement, if any, by
therapeutic development arms of CF patient advocacy groups (and the
maintenance thereof), in the commercialization and acceptance of
new therapies globally, and those set forth in our Annual Report on
Form 10-K for the year ended December 31,
2018, our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2019 and our other SEC
filings. We assume no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-host-cystic-fibrosis-summit-on-disparity-in-access-to-cftr-modulators-based-on-geography-featuring-members-of-the-cystic-fibrosis-community-and-thought-leaders-300941623.html
SOURCE Proteostasis Therapeutics, Inc.